http://www.spandidos-publications.com/10.3892/br.2012.18
Another abstract from a paper "Metformin in non-alcoholic fatty liver disease: A systematic review and meta‑analysis"
Non-alcoholic fatty liver disease (NAFLD) related to insulin resistance (IR) is a growing global health concern. Recent studies have indicated that metformin could improve IR and may be beneficial in the treatment of NAFLD. This study aimed to assess the beneficial or harmful effects of metformin in NAFLD.
Lots of technical stuff next... then the results which are a little worrying
Sub‑analysis of non‑alcoholic fatty steatohepatitis showed that metformin failed to improve any pooled outcome. Adverse events were poorly reported.
Current information indicates that metformin improves liver function, HOMA‑IR and BMI to some extent, but not histological response in NAFLD patients.
Another abstract from a paper "Metformin in non-alcoholic fatty liver disease: A systematic review and meta‑analysis"
Non-alcoholic fatty liver disease (NAFLD) related to insulin resistance (IR) is a growing global health concern. Recent studies have indicated that metformin could improve IR and may be beneficial in the treatment of NAFLD. This study aimed to assess the beneficial or harmful effects of metformin in NAFLD.
Lots of technical stuff next... then the results which are a little worrying
Sub‑analysis of non‑alcoholic fatty steatohepatitis showed that metformin failed to improve any pooled outcome. Adverse events were poorly reported.
Current information indicates that metformin improves liver function, HOMA‑IR and BMI to some extent, but not histological response in NAFLD patients.
